CoChat

Primer Sequence Disclosure: A Clarification of the MIQE Guidelines

Open access
Bustin, Stephen A, Benes, Vladimir, Garson, Jeremy A, Hellemans, Jan, Huggett, Jim, Kubista, Mikael, Mueller, Reinhold, Nolan, Tania, Pfaffl, Michael W, Shipley, Gregory L, Vandesompele, Jo, Wittwer, Carl T · 2011 · Clinical Chemistry
Cited by 76

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

To the Editor: The publication of the minimum information for the publication of real-time quantitative PCR experiments (MIQE)1 guidelines (1) has turned out to be a defining event in the maturing of quantitative real-time PCR (qPCR) technology. The response from instrument and reagent manufacturers has been universally positive. There has been extensive publicity in print, online, and at scientific meetings, and scientific journals are beginning to take note (2). Citations of the MIQE paper are accelerating, with 63 of the 169 citations (as of the end of January 2011) having appeared since September 2010. There is an enormous amount of good will toward this initiative, with many researchers keen to implement the different parameters within their own experimental protocols. MIQE was never conceived with the intent of imposing an immutable edict, as in the spirit of a regulatory agency. The aim was to provide commonsense guidelines for enhancing the reproducibility and transparency of qPCR assays. MIQE, however, has become a marketing and selling argument (“MIQE compliance”), and this practice places a responsibility on the authors of the guidelines to assess whether the rapidly evolving technology demands refinement of the guidelines to acknowledge researchers' uncertainty. Most discussion has concerned the stipulation of primer sequence disclosure. Many commercial qPCR assays are not supplied with the primer/probe sequences because most vendors consider such information commercially sensitive. In addition, there usually are no details provided regarding empirical validation of each individual assay. The increasing use of commercial qPCR assays is creating problems, because it leads to publications that cannot satisfy current MIQE requirements and limits the universal acceptance of MIQE. Consequently, we propose a pragmatic amendment of the original guidelines to require “EITHER primer sequences OR amplicon context sequence.” This proposal is based on our assessment that in the absence of full disclosure of primer sequence, it is possible to achieve an adequate level of transparency, but only if there is an appropriate level of background information and disclosure of validation results regarding the qPCR assay: Our key concern is that today's reports must remain technically accessible in the medium to long term. For that reason, publications must not report assays without reference to sequence data, with invalid Web site references, or with resources obtained from vendors that no longer exist. We continue to affirm that full disclosure of the reagents used and validation of their performance are principal requirements for MIQE “compliance.” Full primer (and probe) sequence disclosure remains our ideal; however, it may be possible to obtain equivalent results from slightly different assays as long as they target the same region and splice variants and they take single-nucleotide polymorphisms and secondary structures into account. Consequently, if primer sequences are not disclosed, a MIQE-compliant publication should provide all of the following: The assay identification provided by the commercial vendor. The specific amplicon context sequence for the qPCR assay. Preferably, this information is obtained by sequencing the target PCR amplicon; alternatively, it could be supplied by the vendor or approximated by the authors (Fig. 1). The same validation criteria used for assays reporting primer/probe sequences. Specifically, when a precise -fold change for a transcript is reported, an essential requirement that remains is that the PCR efficiency, analytical sensitivity, and specificity of each individual assay be determined. Investigators should verify this information for the actual assay being reported under the laboratory conditions their personnel used in their laboratory; they should not extrapolate it from commercial assays validated by the vendors. We introduce the concept of an “anchor nucleotide,” which we define as a nucleotide contained anywhere within the probe sequence. The probe and primers are assumed to be 15 bp and 19 bp, respectively, with a 5-bp gap between them. No assumptions are made with respect to optimal or suboptimal primer or probe sequences. The vendor publishes information regarding reference sequence, anchor nucleotide, and amplicon length, which in this example are NM_001145847.1, 2982, and 100 bp, respectively. A central 29-bp sequence centered on the anchor nucleotide delineates the maximum context sequence for the probe. A 77-bp core sequence consists of 24 bp (19 bp for the primer and 5 bp for the gap between the 3′ end of the primer and the 5′ end of the probe) added to either side of the central sequence. The amplicon context is obtained by adding 23 bp (100−77) to either side of the core sequence to demarcate the potential extent of the PCR amplicon. In this example, the 100-bp amplicon would have a 123-bp context sequence, which is what one would submit with the publicat

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2011.162958

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 76

Metadata

Authors
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., Vandesompele, J., & Wittwer, C. T.
Venue
Clinical Chemistry
Published
2011-06-01
Volume
57
Issue
6
Pages
919-921
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2106962167
Cited by
76
References
1
FWCI
2.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primer Sequence Disclosure: A Clarification of the MIQE Guidelines. https://app.cochat.ai/papers/10.1373/clinchem.2011.162958
The paper
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., Vandesompele, J., & Wittwer, C. T. (2011). Primer Sequence Disclosure: A Clarification of the MIQE Guidelines. Clinical Chemistry. https://doi.org/10.1373/clinchem.2011.162958

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.